Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 29 Parkinson's papers of 227 | 0.55 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 4701
Sealed predictions
- VPS13A in dopamine neurons, braak+0.55 (p 0.122) → +0.42 (p 0.258)receipt 4707
Swarm cases
receipt 4707: VPS13A in dopamine neurons, braak
- power
- full sample +0.49 (p 0.040, n 18), 95% CI +0.03 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.51 (p 0.030, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range +0.43 to +0.67, sign flips 0; without severely affected donors +0.49 (p 0.040, n 18). robust.
- cell type
- strongest in OPCs: -0.62 (p 0.0057, n 18) vs +0.49 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VPS13A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up VPS13A · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.60 p 0.033 (needs p < 4.2e-4)
Receipts
loading the receipts